Oral active matrix metalloproteinase‐8 immunotest may be less accurate in haemato‐oncologic patients

Objectives This study examines the associations of active matrix metalloproteinase‐8 (aMMP‐8) point‐of‐care immunotest (Periosafe) outcomes with oral health of patients with haemato‐oncologic diseases. Methods Adult patients diagnosed with haematological diseases aimed to be treated with haematopoietic stem cell transplantation (HSCT) between 2018 and 2019 were included in the study. Clinical and radiological dental examination were taken immediately prior to transplantation. The presence of oral foci of infections, caries or periodontitis was examined and compared with the outcomes of aMMP‐8 immunotest. Results Acute oral infection foci were present in 11.9%, chronic in 44.1% and periodontitis in 42.0% of the 143 subjects. aMMP‐8 immunotest was positive in 13.3% of all the 143 subjects. Among subjects with periodontitis (n = 60), the aMMP‐8 immunotest was also positive in 13.3% of these subjects. However, the subjects with positive aMMP‐8 immunotest (n = 19) had more often acute or chronic infection foci and more than one of the examined dental treatment needs compared with subjects with negative immunotest (all p